Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?

Panelists discuss how pirtobrutinib is increasingly being considered as a second-line option in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), particularly for patients who have developed resistance or intolerance to covalent Bruton tyrosine kinase (BTK) inhibitors, though the optimal positioning of this noncovalent BTK inhibitor continues to evolve as more real-world experience accumulates.

EP: 1.Expert Insights in Selecting Frontline Therapies in TN CLL: Fixed-Duration Venetoclax vs Continuous BTKi

EP: 2.ASH 2024 Updates: SEQUOIA 5-Year Follow-Up and Expert Perspectives in Selecting Between Acalabrutinib vs Zanubrutinib in TN CLL

EP: 3.Real-World Observations: Firstline cBTKi Switches and Cardiac AEs in TN CLL

EP: 4.Clinical Insights: Exploring Combination Regimens in First-Line Treatment in CLL: SEQUOIA Arm D and BOVen Trials

EP: 5.Key Takeaways From the AMPLIFY Trial at ASH 2024: Fixed-Duration Acalabrutinib Plus Venetoclax With or Without Obinutuzumab vs Chemoimmunotherapy in TN CLL

EP: 6.ASH 2024 Updates: Evaluating Potential Frontline Triplet Regimen: Pirtobrutinib Plus Venetoclax Plus Obinutuzumab in TN CLL

EP: 7.Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice

EP: 8.Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting

EP: 9.ASH 2024 Highlights: Phase 2 Study of Zanubrutinib Plus Venetoclax in R/R CLL

EP: 10.Treatment Sequencing in R/R CLL: Optimizing Strategies and Clinical Insights From ASH 2024 Real-World Data

Now Viewing

EP: 11.Pirtobrutinib in R/R CLL: Can It Be Used in the Second-Line Setting?

EP: 12.Sequencing Treatment in R/R CLL: CAR T-Cell Therapy vs Pirtobrutinib in Double-Exposed Patients

EP: 13.Real-World Observations With Pirtobrutinib and New Data From the BRUIN CLL-321 Trial at ASH 2024

EP: 14.Emerging Data on BTK Inhibitor Degraders and Bispecifics in R/R CLL: Updated Results at ASH 2024

EP: 15.Reflecting on 2024 in CLL: Key Advances and Looking Ahead to 2025

Video content above is prompted by the following:

• Panelists discuss how pirtobrutinib is increasingly being considered as a second-line option in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), particularly for patients who have developed resistance or intolerance to covalent Bruton tyrosine kinase (BTK) inhibitors, though the optimal positioning of this noncovalent BTK inhibitor continues to evolve as more real-world experience accumulates.

Related Videos

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment